| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/15/2003 | EP1274980A1 Solution and crystal structures of mmp-13 active site and uses thereof |
| 01/15/2003 | EP1274862A1 Control of a gene induced by oxidized lipids in human artery wall cells |
| 01/15/2003 | EP1274861A1 Compositions and methods for identifying and targeting cancer cells |
| 01/15/2003 | EP1274849A2 Protein phosphatases |
| 01/15/2003 | EP1274842A2 Lipid binding protein 4 |
| 01/15/2003 | EP1274841A2 Regulation of human cyslt2-like gpcr protein |
| 01/15/2003 | EP1274834A1 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
| 01/15/2003 | EP1274724A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
| 01/15/2003 | EP1274711A1 New aza-indolyl derivatives |
| 01/15/2003 | EP1274458A2 Compositions containing a naphthalmide and an antiproliferative agent |
| 01/15/2003 | EP1274457A2 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
| 01/15/2003 | EP1274456A2 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
| 01/15/2003 | EP1274455A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 01/15/2003 | EP1274451A1 Sperm factor oscillogenin |
| 01/15/2003 | EP1274450A2 Cytokine uses; compositions; methods |
| 01/15/2003 | EP1274444A1 Compounds for the treatment of psychiatric or substance abuse disorders |
| 01/15/2003 | EP1274441A1 Respiratory compositions |
| 01/15/2003 | EP1274440A1 Medical combinations comprising tiotropium and mometasone |
| 01/15/2003 | EP1274435A1 Medical combinations comprising formoterol and budesonide |
| 01/15/2003 | EP1274434A1 Medical combinations comprising tiotropium and rofleponide |
| 01/15/2003 | EP1274430A2 Compounds for treating fibromyalgia and chronic fatigue syndrome |
| 01/15/2003 | EP1274425A1 Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor |
| 01/15/2003 | EP1274421A2 Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses |
| 01/15/2003 | EP1274420A1 Microbial inhibitory compositions |
| 01/15/2003 | EP1274417A2 Treatment of movement disorders with metabotropic glutamate receptor antagonists |
| 01/15/2003 | EP1274414A1 Nasal administration of agents for the treatment of gastroparesis |
| 01/15/2003 | EP1274412A1 Pharmaceutical formulation |
| 01/15/2003 | EP1274405A2 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 01/15/2003 | EP1274404A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents |
| 01/15/2003 | EP1063998B1 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
| 01/15/2003 | EP1063995B1 Combination for the treatment of alcohol dependence containing an opioid antagonist and a nmda receptor complex modulator |
| 01/15/2003 | EP1009524B1 Improvements in or relating to capsules |
| 01/15/2003 | EP0977597B1 Improved methods for diagnostic imaging using a contrast agent and a vasodilator |
| 01/15/2003 | EP0851756B1 Use of ondansetron in the manufacture of a medicament for the treatment of tremor |
| 01/15/2003 | EP0817636B1 Cinnamoyl-c-glycoside chromone isolated from aloe barbadensis |
| 01/15/2003 | CN1391487A Methods for treating therapy-resistant tumors |
| 01/15/2003 | CN1391486A Methods for treating therapy-resistant tumors |
| 01/15/2003 | CN1391484A Method of potentiating chemotherapy and treating solid tumors |
| 01/15/2003 | CN1391482A Therapy |
| 01/15/2003 | CN1391479A Medicament for inducing tolerance |
| 01/15/2003 | CN1391475A Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| 01/15/2003 | CN1391470A Pharmaceutical composition and method for treatment of inflammation |
| 01/15/2003 | CN1391468A Pharmaceutical compositions comprising adenosine receptor agonist or antagonist |
| 01/15/2003 | CN1391464A Formulation for menopausal women |
| 01/15/2003 | CN1390837A Anti-inflammatory and antineoplastic R-bis or glycophenylpropane isoselenazole substituted compound |
| 01/14/2003 | US6506803 Methods of preventing and treating microbial infections |
| 01/14/2003 | US6506796 Cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of |
| 01/14/2003 | US6506788 N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders |
| 01/14/2003 | US6506781 Prevent formation of a hydrogen bond between the agonist and tyrosine or histidine, or tryptophan involved in receptor activation; and/or b) displace the tyrosine or histidine, or tryptophan involved in receptor activation from its agonist |
| 01/14/2003 | US6506778 Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals |
| 01/14/2003 | US6506774 The use of orexin receptor antagonists as neuroprotectants, and in the treatment of nausea and vomiting, irritable bowel syndrome and other conditions associated with visceral pain. |
| 01/14/2003 | US6506765 Apomorphine derivatives and methods for their use |
| 01/14/2003 | US6506739 Compounds possess anti-tumor activities or are capable of being modified to have anti-tumor activities; and this invention relates to the use of the compounds in methods for the treatment of tumors and, especially, for the treatment of |
| 01/14/2003 | US6506724 Exendins are peptides that were first isolated from the salivary secretions of the Gila-monster, a lizard found in Arizona and have some sequence similarity to several members of the glucagon-like peptide |
| 01/14/2003 | US6506587 Nucleotide sequences coding enzymatic polypeptide; for use as an antitumor a gents |
| 01/14/2003 | US6506549 Sodium, calcium, chloride, potassium, albumin, and sugar; plasmaphoresis |
| 01/14/2003 | US6506412 Treatment of dry eye syndrome |
| 01/14/2003 | US6506411 Anti-angiogenic compositions and methods of use |
| 01/14/2003 | US6506410 Sustained release microparticle and method for preparing the same |
| 01/14/2003 | CA2222303C Use of at least one no synthase inhibitor for treating sensitive skin |
| 01/14/2003 | CA2065270C Erection-inducing methods and compositions |
| 01/14/2003 | CA2056322C Ginkgo biloba acting as alpha-2-blocker slimming compound |
| 01/13/2003 | CA2393376A1 Assay methods |
| 01/09/2003 | WO2003003018A2 Method for identifying compounds for the therapy of aging of the cardiovascular system |
| 01/09/2003 | WO2003003016A1 Diagnostic methods and agents |
| 01/09/2003 | WO2003003010A1 Pael receptor, cells and animal expressing pael receptor and method of screening remedy for parkinson’s disease |
| 01/09/2003 | WO2003003006A2 New potent, selective and non toxic c-kit inhibitors |
| 01/09/2003 | WO2003003004A2 Method for identifying compounds the specifically deplete mast cells |
| 01/09/2003 | WO2003002765A2 Methods for the diagnosis of cancer based on the obcam and ntm genes |
| 01/09/2003 | WO2003002756A1 Fkbp51/52 and cyp40-mediated mammalian hair growth |
| 01/09/2003 | WO2003002755A2 Glaucoma treatments with reduced hyperpigmentation |
| 01/09/2003 | WO2003002742A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 01/09/2003 | WO2003002722A2 T cell regulatory genes and methods of use thereof |
| 01/09/2003 | WO2003002713A2 Antibodies to opgl |
| 01/09/2003 | WO2003002610A1 Extracellular messengers |
| 01/09/2003 | WO2003002596A2 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 01/09/2003 | WO2003002595A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/09/2003 | WO2003002175A2 Enhanced systemic absorption of intradermally delivered substances |
| 01/09/2003 | WO2003002158A1 The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| 01/09/2003 | WO2003002148A1 Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
| 01/09/2003 | WO2003002146A1 Medicinal compositions |
| 01/09/2003 | WO2003002142A1 Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes |
| 01/09/2003 | WO2003002135A2 Herbal composition |
| 01/09/2003 | WO2003002129A1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002116A1 Zonisamide use in headache |
| 01/09/2003 | WO2003002114A2 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 01/09/2003 | WO2003002110A1 METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D¿2? |
| 01/09/2003 | WO2003002109A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | WO2003002108A2 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | WO2003002107A2 Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
| 01/09/2003 | WO2003002106A2 Use of tyrosine kinase inhibitions for treating allergic diseases |
| 01/09/2003 | WO2003002105A2 Use of tyrosine kinase inhibitors for treating bone loss |
| 01/09/2003 | WO2003002103A2 Hydrophobic dopamine agonists administered to the dermis |
| 01/09/2003 | WO2003002102A1 Sustained release pharmaceutical composition |
| 01/09/2003 | WO2003002100A1 Tamper-proof narcotic delivery system |
| 01/09/2003 | WO2003002094A2 Enhanced pharmacokinetic profile of hydrophobic substances |
| 01/09/2003 | WO2003002092A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 01/09/2003 | WO2003002065A2 Hcv e1e2 vaccine compositions |
| 01/09/2003 | WO2003002060A2 Method of treating malignancy associated hypercalcemia using active vitamin d analogues |